Biotech stocks in trouble? Immatics shares plunge after $150m funding news shocks investors

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on cancer immunotherapies, has seen its shares decline significantly after announcing a $150 million public offering. ... Read More